64 related articles for article (PubMed ID: 21173141)
1. Fixation time does not affect the expression of estrogen receptor.
Dabbs DJ; Bhargava R
Am J Clin Pathol; 2011 Jan; 135(1):171-2; author reply 172. PubMed ID: 21173141
[No Abstract] [Full Text] [Related]
2. Fixation time does not affect the expression of estrogen receptor.
Ibarra JA; Rogers LW; Kyshtoobayeva A; Bloom K
Am J Clin Pathol; 2010 May; 133(5):747-55. PubMed ID: 20395521
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen receptor beta: how should we measure this?
Speirs V; Carder PJ; Lansdown MR
Br J Cancer; 2002 Sep; 87(6):687; author reply 688-9. PubMed ID: 12237781
[No Abstract] [Full Text] [Related]
4. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
5. Fixation time does not affect expression of HER2/neu.
Goldsmith JD; Allred DC; Beasley MB; Eisen R; Fulton RS; Gown AM; Hammond ME
Am J Clin Pathol; 2011 Mar; 135(3):484; author reply 485. PubMed ID: 21350107
[No Abstract] [Full Text] [Related]
6. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer.
Grewal J; Zhou H; Factor R; Kesari S
J Clin Oncol; 2010 May; 28(13):e200-2. PubMed ID: 20124173
[No Abstract] [Full Text] [Related]
7. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Goldstein NS; Ferkowicz M; Odish E; Mani A; Hastah F
Am J Clin Pathol; 2003 Jul; 120(1):86-92. PubMed ID: 12866377
[TBL] [Abstract][Full Text] [Related]
8. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers as predictive tools for breast cancer.
Walker RA
J Clin Pathol; 2008 Jun; 61(6):689-96. PubMed ID: 18037665
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two score systems in Bcl-2 and Bax protein expression in invasive ductal carcinoma of breast and relation with oestrogen and progestrone receptors.
Ayatollahi H; Ghaffarzadegan K; Sharifi N; Farahmand MJ; Jarafian AH
Breast J; 2009; 15(3):310-2. PubMed ID: 19645793
[No Abstract] [Full Text] [Related]
12. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?
Rhodes A; Jasani B
J Clin Pathol; 2009 Jan; 62(1):95-6. PubMed ID: 19103868
[No Abstract] [Full Text] [Related]
13. Comparison of molecular markers expression in vacuum-assisted biopsies and surgical specimens of human breast carcinomas.
Zagouri F; Sergentanis TN; Nonni A; Papadimitriou CA; Michalopoulos NV; Giannakopoulou G; Bletsa G; Patsouris E; Zografos GC
Pathol Res Pract; 2010 Jan; 206(1):30-3. PubMed ID: 19836148
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
15. Pathological definition of triple negative breast cancer.
Viale G; Bottiglieri L
Eur J Cancer; 2009 Sep; 45 Suppl 1():5-10. PubMed ID: 19775600
[No Abstract] [Full Text] [Related]
16. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
17. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
18. Comparing the clinical, histopathological and myoepithelial features of estrogen receptor positive and negative mammary carcinomas.
Gucin Z; Aksoy B; Gunver F; Pasaoglu E; Bahadir F
Saudi Med J; 2006 Apr; 27(4):470-6. PubMed ID: 16598322
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?
Park BW; Kim KS; Heo MK; Ko SS; Hong SW; Yang WI; Kim JH; Kim GE; Lee KS
Breast Cancer Res Treat; 2003 Jul; 80(1):79-85. PubMed ID: 12889601
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
